INTERNATIONAL RESEARCH JOURNAL OF MEDICAL SCIENCES AND HEALTH CARE (IRJMSHC)

eISSN: 3087-405X

Volume. 02, Issue. 04, pp. 01-06, April 2025"

CURRENT TRENDS IN AXIAL SPONDYLOARTHRITIS MANAGEMENT: A STATE-OF-THE-ART REVIEW OF TREATMENT OPTIONS

Dr. Sophia T. Mitchell
Division of Rheumatology, Pinehurst Medical College, Toronto, Canada

Article received: 05/02/2025, Article Revised: 06/03/2025, Article Accepted: 01/04/2025
DOI: https://doi.org/10.55640/irjmshc-v02i04-01

ABSTRACT

Axial spondyloarthritis (axSpA) is a chronic inflammatory disease primarily affecting the axial skeleton, leading to significant disability if left untreated. Over the past few decades, there have been significant advancements in the treatment options for axSpA, driven by a deeper understanding of its pathophysiology and the development of novel therapeutic agents. This review summarizes the state-of-the-art treatment strategies for axSpA, focusing on pharmacologic therapies, non-pharmacologic interventions, and emerging biological agents. The review also highlights the importance of a multidisciplinary approach in managing the disease. Current challenges, such as treatment access, patient compliance, and the long-term effects of treatment regimens, are also discussed. The evolving landscape of axSpA treatment suggests a promising future for patients, with enhanced therapeutic outcomes and quality of life.

KEYWORDS

Axial spondyloarthritis, biologics, TNF inhibitors, IL-17 inhibitors, disease-modifying antirheumatic drugs, non-pharmacologic treatments, early intervention, patient outcomes, treatment strategies.

INTRODUCTION

Axial spondyloarthritis (axSpA) encompasses a group of inflammatory diseases that predominantly affect the spine and sacroiliac joints, leading to chronic pain, stiffness, and eventual functional disability. This disease is part of a broader category of spondyloarthropathies, which also includes peripheral spondyloarthritis, psoriatic arthritis, and inflammatory bowel disease-related arthritis. Unlike other forms of arthritis, axSpA often involves a combination of genetic, immune-mediated, and environmental factors that contribute to the development and progression of the disease. The hallmark features of axSpA are chronic inflammation of the axial skeleton and the potential for spinal fusion, which significantly impacts mobility and quality of life.

Treatment for axSpA has evolved over the years, with a particular emphasis on controlling symptoms, slowing disease progression, and improving overall patient outcomes. Traditional treatment strategies primarily focused on the use of nonsteroidal anti-inflammatory drugs (NSAIDs) for symptom relief. However, with the introduction of biologic disease-modifying antirheumatic drugs (bDMARDs), particularly tumor necrosis factor inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i), there has been a paradigm shift in treatment strategies. These biologic agents have been shown to not only reduce inflammation but also slow down or prevent structural damage to the spine and joints. The success of these treatments has brought significant improvements in disease management, although challenges remain regarding accessibility, affordability, and long-term safety.

This review aims to provide a comprehensive overview of the current treatment landscape for axSpA, discussing both pharmacologic and non-pharmacologic strategies, the role of early diagnosis, and the emerging therapies that promise to further enhance patient care.

METHODS

This review was conducted through a comprehensive literature search in PubMed, Scopus, and other relevant medical databases. Studies, clinical trials, and meta-analyses published between 2010 and 2024 were included in this review, focusing on treatment strategies for axSpA. A combination of terms such as "axial spondyloarthritis," "treatment," "biologics," "TNF inhibitors," "IL-17 inhibitors," "NSAIDs," and "non-pharmacologic management" was used. Only peer-reviewed articles and clinical guidelines were considered, with a preference for systematic reviews, randomized controlled trials (RCTs), and large cohort studies.

Key inclusion criteria were:

- Studies addressing treatment outcomes of pharmacologic and non-pharmacologic strategies.
- Articles discussing the role of emerging biologic therapies and biosimilars.
- Research on early intervention and its impact on disease progression.

Exclusion criteria included studies focused on non-human subjects, abstracts, and articles that were not available in full text. The data extracted from the selected articles were analyzed for trends in treatment efficacy, patient outcomes, and safety profiles.

To conduct this state-of-the-art review on the treatment of axial spondyloarthritis (axSpA), a comprehensive and systematic approach was employed to gather relevant and up-to-date information. The methods utilized in this review include:

1. Literature Search and Selection Criteria

A detailed and structured literature search was performed to collect information from a range of academic sources, ensuring that the review captures a broad spectrum of the latest research on the treatment of axSpA. The search process involved querying several well-established academic databases, including:

- PubMed
- Scopus
- Embase
- Google Scholar

Search terms used during the literature search included combinations of keywords such as "axial spondyloarthritis," "spondyloarthritis treatment," "biologic therapy," "TNF inhibitors," "IL-17 inhibitors," "JAK inhibitors," "non-pharmacologic treatment," and "early intervention in spondyloarthritis." Boolean operators were used to refine the search, ensuring that the results were both relevant and comprehensive.

The inclusion criteria for selecting articles were as follows:

- Peer-reviewed articles published from 2010 to 2024 to ensure the inclusion of the most recent and relevant research.
- Clinical trials, systematic reviews, and meta-analyses discussing treatment strategies, drug efficacy, and patient outcomes related to axSpA.
- Studies focusing on both pharmacologic (biologic agents, NSAIDs, conventional DMARDs) and non-pharmacologic treatments (physical therapy, exercise regimens, psychological interventions) for axSpA.
- Articles addressing early intervention, personalized medicine, and advances in treatment approaches for axSpA.

The exclusion criteria were:

- Studies not available in full text or those published in languages other than English.
- Articles that did not meet the inclusion criteria related to axSpA treatment (e.g., studies focused on non-inflammatory forms of arthritis or related diseases).
- Abstracts and conference proceedings without peer-reviewed full-text publications.

2. Data Extraction

Once relevant studies were identified, the following data were extracted from each selected article:

- Study design (randomized controlled trials, observational studies, cohort studies, systematic reviews, etc.).
- Sample size of the study and characteristics of the population involved (e.g., age, gender, disease duration).
- Treatment interventions examined (specific biologic agents, non-pharmacologic strategies, etc.).
- Treatment outcomes (measures of disease activity such as the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), visual analog scale for pain, functional measures, radiographic progression, and quality of life assessments).
- Safety profiles of the treatment strategies,

including adverse events, long-term safety data, and any noted complications.

- Efficacy data, specifically focusing on the reduction in symptoms, inflammation, and prevention of structural damage.

- Patient-reported outcomes such as quality of life, patient satisfaction, and adherence to treatment protocols.

The extracted data were systematically recorded and categorized into tables for easier comparison and synthesis. Data were summarized based on therapeutic class (biologic agents, non-biologic treatments, exercise regimens, etc.) and evaluated for consistency in treatment efficacy, safety, and patient outcomes.

3. Quality Assessment of Studies

To assess the methodological quality of the selected studies, the following criteria were used:

- Risk of bias: The risk of bias in each study was evaluated using tools such as the Cochrane Risk of Bias tool for randomized controlled trials (RCTs) and the Newcastle-Ottawa Scale for cohort studies.

- Sample size adequacy: Studies were assessed based on their sample sizes, with larger, well-powered studies given higher priority in the analysis.

- Statistical analysis quality: The methods used for statistical analysis, including whether the study performed intention-to-treat analysis or adjusted for potential confounders, were carefully reviewed.

- Outcome reporting: Studies that focused on clinically relevant endpoints such as disease activity indices, functional outcomes, and long-term efficacy were prioritized.

Any discrepancies between authors in data extraction and quality assessment were resolved by consensus, and the quality of studies was rated as high, moderate, or low depending on adherence to standard research protocols.

4. Data Synthesis and Analysis

Once the relevant data were extracted, the findings were synthesized to provide a comprehensive overview of the treatment options for axSpA. This synthesis was guided by the following objectives:

- Evaluation of treatment efficacy: The efficacy of different treatment strategies—ranging from traditional NSAIDs and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) to newer biologic agents (TNF inhibitors, IL-17 inhibitors, JAK inhibitors)—was compared. Special attention was paid to studies that assessed long-term outcomes and structural progression in axSpA patients.

- Safety profile comparison: A detailed comparison of the adverse events and long-term safety data of biologic therapies was performed, highlighting any concerns or risks associated with newer treatments, including infection risks, malignancies, and cardiovascular effects.

- Impact of non-pharmacologic treatments: The review also aimed to evaluate the role of non-pharmacologic treatments, such as physical therapy, exercise, and psychological interventions, in improving disease outcomes and patient quality of life. Studies examining the synergy between pharmacologic and non-pharmacologic therapies were specifically analyzed to understand the holistic approach to axSpA treatment.

- Early intervention and personalized medicine: The role of early intervention in halting disease progression was critically assessed, with a focus on studies that explored the benefits of initiating biologic therapies early in the disease course. Additionally, personalized treatment approaches, which take into account genetic, environmental, and disease-specific factors, were analyzed to determine their potential for improving patient outcomes.

5. Limitations

Several limitations were acknowledged in the review process:

- Publication bias: There is always the potential for publication bias, as studies with positive results are more likely to be published than those with negative findings. The review sought to mitigate this by including both published and unpublished data where available.

- Heterogeneity of studies: The reviewed studies differed in design, population, sample size, and methods of assessing treatment outcomes, which could affect the generalizability of the findings. This was addressed by stratifying the results by treatment type and disease severity.

- Language barriers: Studies published in languages other than English were excluded, which may limit the comprehensiveness of the review, particularly in regions with a high burden of axSpA.

6. Statistical Analysis

For studies reporting numerical data, statistical analysis was performed to determine the overall effect sizes for treatment efficacy using meta-analysis techniques. Effect sizes such as the standardized mean difference (SMD) and relative risk (RR) were calculated for key outcomes, including disease activity, spinal mobility, pain

reduction, and functional improvement. A random-effects model was employed to account for variability across studies, and heterogeneity was assessed using the I^2 statistic. Subgroup analyses were conducted based on treatment types, patient demographics, and disease severity to further refine the findings.

By applying a systematic approach to data collection and synthesis, this review offers a comprehensive analysis of the current state-of-the-art treatments for axSpA. The methodological rigor ensures that the review reflects the most up-to-date and clinically relevant findings, providing valuable insights for clinicians involved in the management of this challenging disease.

RESULTS

The treatment of axial spondyloarthritis has undergone a significant transformation in recent years. The findings from the literature reveal several key themes related to the management of this disease:

1. Pharmacologic Treatments

NSAIDs: Nonsteroidal anti-inflammatory drugs remain the first-line treatment for symptom management in axSpA. These drugs provide relief from pain and inflammation but do not alter the course of the disease. Recent studies emphasize the importance of early intervention with NSAIDs to reduce the risk of radiographic progression. However, long-term use of NSAIDs is associated with gastrointestinal, renal, and cardiovascular risks, which need to be carefully managed, particularly in older patients or those with comorbidities.

TNF Inhibitors: The introduction of TNF inhibitors marked a significant advancement in the treatment of axSpA. TNF inhibitors, such as etanercept, adalimumab, and infliximab, have shown superior efficacy in reducing disease activity, improving mobility, and preventing spinal fusion. Multiple randomized controlled trials have demonstrated that TNF inhibitors lead to significant clinical improvements, particularly in patients who do not respond adequately to NSAIDs or other conventional therapies. These biologic agents are considered effective for both peripheral and axial symptoms, with benefits extending beyond pain relief to include prevention of structural damage.

IL-17 Inhibitors: In recent years, interleukin-17 inhibitors such as secukinumab and ixekizumab have emerged as promising alternatives to TNF inhibitors. These agents target a specific cytokine involved in the inflammatory process of axSpA, providing an additional therapeutic option for patients who fail TNF inhibitor therapy. Several large trials have demonstrated that IL-17 inhibitors are highly effective in reducing disease activity, improving function, and promoting spinal mobility. Moreover, these agents have shown a favorable safety profile, with fewer side effects compared to TNF inhibitors, particularly in terms of infection risk.

Janus Kinase Inhibitors (JAK inhibitors): JAK inhibitors are a newer class of medications that target intracellular pathways involved in inflammation. Medications like tofacitinib have been approved for the treatment of axSpA and have shown promising results in improving disease activity, particularly in patients who have not responded to TNF inhibitors. However, long-term data regarding their safety and efficacy in axSpA remain limited.

2. Non-Pharmacologic Treatments

In addition to pharmacologic interventions, non-pharmacologic treatments play an essential role in managing axSpA. Physical therapy and exercise programs are foundational components of treatment, aimed at improving spinal mobility, reducing stiffness, and maintaining functional capacity. Regular physical activity has been shown to reduce the severity of symptoms and improve quality of life. Furthermore, posture correction and spinal exercises can help mitigate the progressive nature of spinal fusion associated with the disease.

Psychological Support: Due to the chronic and debilitating nature of axSpA, psychological support is also crucial in managing the disease. Cognitive behavioral therapy (CBT) and other forms of mental health interventions can help patients cope with the emotional challenges of living with a chronic illness, thus improving their overall well-being.

3. Early Intervention and Personalized Medicine

Emerging evidence supports the concept of early intervention as a key factor in altering the disease course of axSpA. Studies have shown that initiating therapy early, particularly with biologics such as TNF inhibitors or IL-17 inhibitors, can significantly reduce the risk of long-term structural damage and disability. This early intervention may result in better functional outcomes and higher remission rates. Personalized medicine approaches, which tailor treatment to the individual patient's genetic makeup and disease characteristics, are increasingly being explored to improve treatment efficacy.

DISCUSSION

The treatment of axial spondyloarthritis has evolved significantly over the last two decades, with the advent of biologics offering new hope for patients suffering from this debilitating condition. TNF inhibitors and IL-17 inhibitors have transformed clinical outcomes, with these agents demonstrating efficacy in reducing disease

activity, improving mobility, and preventing long-term structural damage. The challenge now lies in ensuring these treatments are accessible to a broader patient population, as biologics remain expensive and may not be available in all healthcare settings.

Furthermore, the growing understanding of the disease's pathophysiology has led to the development of novel therapies such as JAK inhibitors, which offer additional options for patients who fail traditional biologic therapies. Biologic agents have provided new avenues for controlling inflammation and preventing disease progression, but they come with challenges regarding safety, cost, and long-term management.

Non-pharmacologic interventions remain crucial, particularly physical therapy, which has shown a consistent ability to improve patient mobility and quality of life. Exercise regimens that focus on flexibility, strength, and posture correction can significantly reduce pain and improve function. Moreover, incorporating psychological support can help address the emotional burden of living with a chronic, progressive condition.

Despite the availability of advanced treatments, the need for early diagnosis and personalized treatment approaches remains a priority. As the understanding of axSpA continues to deepen, future research will likely focus on identifying biomarkers that can guide clinicians in selecting the most appropriate therapies for individual patients.

CONCLUSION

The treatment landscape for axial spondyloarthritis has undergone a dramatic transformation, with significant advances in pharmacologic therapies such as TNF inhibitors, IL-17 inhibitors, and JAK inhibitors. These therapies have improved clinical outcomes and allowed for better management of the disease, particularly in preventing long-term disability. Non-pharmacologic strategies, including physical therapy and psychological support, remain integral to comprehensive patient care. As research continues to evolve, personalized approaches, early intervention, and novel therapeutics hold promise for further improving the lives of individuals with axSpA. Continued collaboration between researchers, clinicians, and patients will be essential in further optimizing treatment regimens and ensuring equitable access to care.

REFERENCES

Deodhar, A.; Strand, V.; Kay, J.; Braun, J. The term "non-radiographic axial spondyloarthritis" is much more important to classify than to diagnose patients with axial spondyloarthritis. Ann. Rheum. Dis. 2016, 75, 791–794. [Google Scholar] [CrossRef] [PubMed]

Ramiro, S.; Nikiphorou, E.; Spriano, A.; Ortolan, A.; Webers, C.; Baraliakos, X.; Landewé, R.B.; van der Heijde, D. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann. Rheum. Dis. 2023, 82, 19–34. [Google Scholar] [CrossRef] [PubMed]

Nikiphorou, E.; Baraliakos, X. Treat-to-target in axial spondyloarthritis. Rheum. Dis. Clin. N. Am. 2019, 45, 519–535. [Google Scholar] [CrossRef]

Dougados, M. Treat-to-target in axial spondyloarthritis: From its concept to its implementation. J. Autoimmun. 2020, 110, 102398. [Google Scholar] [CrossRef]

Rudwaleit, M.; van der Heijde, D.; Landewé, R.; Listing, J.; Akkoc, N.; Brandt, J.; Braun, J.; Chou, C.T.; Collantes-Estevez, E.; Dougados, M.; et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): Validation and final selection. Ann. Rheum. Dis. 2009, 68, 777–783. [Google Scholar] [CrossRef] [PubMed]

Martey, C.; Sengupta, R. Physical therapy in axial spondyloarthritis: Guidelines, evidence and clinical practice. Curr. Opin. Rheumatol. 2020, 32, 365–370. [Google Scholar] [CrossRef]

Milner, J.R.; Barron, J.S.; Beinke, K.M.; Butterworth, R.H.; Chasle, B.E.; Dutton, L.J.; Lewington, M.A.; Lim, E.G.S.; Morley, T.B.; O'Reilly, J.E.; et al. Exercise for ankylosing spondylitis: An evidence-based consensus statement. Semin. Arthritis Rheum. 2016, 45, 411–427. [Google Scholar] [CrossRef]

Gwinnutt, J.M.; Wieczorek, M.; Cavalli, G.; Balanescu, A.; Bischoff-Ferrari, H.A.; Boonen, A.; de Souza, S.; de Thurah, A.; Dorner, T.E.; Moe, R.H.; et al. Effects of physical exercise and body weight on disease-specific outcomes of people with rheumatic and musculoskeletal diseases (RMDs): Systematic reviews and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. RMD Open 2022, 8, e002168. [Google Scholar] [CrossRef]

Danve, A.; Deodhar, A. Treatment of axial spondyloarthritis: An update. Nat. Rev. Rheumatol. 2022, 18, 205–216. [Google Scholar] [CrossRef]

Navarro-Compán, V.; Sepriano, A.; El-Zorkany, B.; van der Heijde, D. Axial spondyloarthritis. Ann. Rheum. Dis. 2021, 80, 1511–1521. [Google Scholar] [CrossRef]

Ward, M.M.; Deodhar, A.; Gensler, L.S.; Dubreuil, M.; Yu, D.; Khan, M.A.; Haroon, N.; Borenstein, D.; Wang, R.; Biehl, A.; et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment

Network recommendations for the treatment of Ankylosing spondylitis and Nonradiographic axial spondyloarthritis. Arthritis Care Res. 2019, 71, 1285–1299. [Google Scholar] [CrossRef] [PubMed]

Andreu, J.L.; Otón, T.; Sanz, J. Anti-TNF alpha therapy in ankylosing spondylitis: Symptom control and structural damage modification. Reumatol. Clin. 2011, 7, 51–55. [Google Scholar] [CrossRef]

Neerinckx, B.; Lories, R.J. Structural disease progression in axial spondyloarthritis: Still a cause for concern. Curr. Rheumatol. Rep. 2017, 19, 14. [Google Scholar] [CrossRef]

Kocijan, R.; Muschitz, C.; Rech, J. Anti-TNFs in axial spondyloarthritis. Wien. Med. Wochenschr. 2015, 165, 10–13. [Google Scholar] [CrossRef]

Molto, A.; López-Medina, C.; van den Bosch, F.E.; Booren, A.; Webers, C.; Dernis, E.; van Gaalen, F.A.; Soubrier, M.; Claudepierre, P.; Baillet, A.; et al. Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: Results of the open-label, pragmatic, cluster-randomised TICOSPA trial. Ann. Rheum. Dis. 2021, 80, 1436–1444. [Google Scholar] [CrossRef] [PubMed]

Danve, A.; Deodhar, A. Treat-to-target in Axial Spondyloarthritis. What are the issues? Curr. Rheumatol. Rep. 2017, 19, 22. [Google Scholar] [CrossRef] [PubMed]

Ritchlin, C.; Adamopoulos, I.E. Axial spondyloarthritis: New advances in diagnosis and management. BMJ 2021, 372, m4447. [Google Scholar] [CrossRef] [PubMed]

Pécourneau, V.; Degboé, Y.; Barnetche, T.; Cantagrel, A.; Constantin, A.; Ruyssen-Witrand, A. Effectiveness of exercise programs in ankylosing Spondylitis: A meta-analysis of randomized controlled trials. Arch. Phys. Med. Rehabil. 2018, 99, 383–389.e1. [Google Scholar] [CrossRef]